Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Endocrinol Invest ; 45(1): 125-137, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34213743

ABSTRACT

PURPOSE: The study aimed to define the clinical, biochemical and genetic features of adult patients with osteopenia/osteoporosis and/or bone fragility and low serum alkaline phosphatase (sALP). METHODS: Twenty-two patients with at least two sALP values below the reference range were retrospectively enrolled after exclusion of secondary causes. Data about clinical features, mineral and bone markers, serum pyridoxal-5'-phosphate (PLP), urine phosphoethanolamine (PEA), lumbar and femur bone densitometry, and column X-ray were collected. Peripheral blood DNA of each participant was analyzed to detect ALPL gene anomalies. RESULTS: Pathogenic ALPL variants (pALPL) occurred in 23% and benign variants in 36% of patients (bALPL), while nine patients harbored wild-type alleles (wtALPL). Fragility fractures and dental anomalies were more frequent in patients harboring pALPL and bALPL than in wtALPL patients. Of note, wtALPL patients comprised women treated with tamoxifen for hormone-sensitive breast cancer. Mineral and bone markers were similar in the three groups. Mean urine PEA levels were significantly higher in patients harboring pALPL than those detected in patients harboring bALPL and wtALPL; by contrast, serum PLP levels were similar in the three groups. A 6-points score, considering clinical and biochemical features, was predictive of pALPL detection [P = 0.060, OR 1.92 (95% CI 0.972, 3.794)], and more significantly of pALPL or bALPL [P = 0.025, OR 14.33 (95% CI 1.401, 14.605)]. CONCLUSION: In osteopenic/osteoporotic patients, single clinical or biochemical factors did not distinguish hypophosphatasemic patients harboring pALPL or bALPL from those harboring wtALPL. Occurrence of multiple clinical and biochemical features is predictive of ALPL anomalies, and, therefore, they should be carefully identified. Tamoxifen emerged as a hypophosphatasemic drug.


Subject(s)
Alkaline Phosphatase/genetics , Biomarkers/analysis , Hypophosphatemia , Alkaline Phosphatase/analysis , Alkaline Phosphatase/blood , Biomarkers/blood , Bone Density , Bone Diseases, Metabolic/blood , Bone Diseases, Metabolic/epidemiology , Bone Diseases, Metabolic/genetics , Chronic Disease , Cross-Sectional Studies , DNA Mutational Analysis , Female , Fractures, Bone/blood , Fractures, Bone/epidemiology , Fractures, Bone/genetics , Humans , Hypophosphatemia/blood , Hypophosphatemia/diagnosis , Hypophosphatemia/epidemiology , Hypophosphatemia/genetics , Italy/epidemiology , Male , Middle Aged , Osteoporosis/blood , Osteoporosis/epidemiology , Osteoporosis/genetics , Polymorphism, Single Nucleotide , Pyridoxal Phosphate/analysis , Pyridoxal Phosphate/blood , Retrospective Studies
2.
J Endocrinol Invest ; 43(11): 1631-1636, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32319047

ABSTRACT

PURPOSE: Serum-negative-chronic-autoimmune-thyroiditis (SN-CAT) is considered a milder variant of classic Hashimoto's thyroiditis (CHT). However, its prevalence remains unknown and it is still unclear whether SN-CAT behaves differently in terms of L-thyroxine (LT4) substitution treatment of hypothyroidism. Aims of this study were to estimate the prevalence of SN-CAT in a large series of hypothyroid patients and to compare LT4 requirements in hypothyroid patients with SN-CAT and CHT. METHODS: Five-hundred-eighty-one consecutive patients with primary-autoimmune-hypothyroidism were enrolled in a cross-sectional study. LT4 requirements and thyroid-volume changes were longitudinally evaluated in 49 hypothyroid patients with SN-CAT and in 98 sex and age-matched hypothyroid patients with CHT. RESULTS: In our series the prevalence of SN-CAT was 20.8%. At diagnosis, patients in the CHT and SN-CAT groups had similar male/female ratio, age and BMI, while serum TSH and thyroid-volume were significantly greater in the CHT group. In the longitudinal study, during a follow-up of 8.9 ± 4.6 years, 8 out of 49 (16.3%) SN-CAT patients developed positive tests for of circulating TPO-Ab and/or Tg-Ab. Thyroid-volume significantly decreased in CHT patients, but not in those with SN-CAT. The maximum daily substitution dose of LT4 was smaller in SN-CAT patients as compared with the CHT ones. Multivariate analysis showed that age, BMI, basal TSH and thyroid antibody status independently and significantly predicted the maximum daily substitution dose of LT4. CONCLUSIONS: SN-CAT accounts for a significant proportion of patients with autoimmune hypothyroidism. Compared with hypothyroid patients diagnosed with CHT, the SN-CAT ones require smaller doses of LT4 to correct their hypothyroidism.


Subject(s)
Hashimoto Disease/drug therapy , Thyroiditis, Autoimmune/drug therapy , Thyroxine/administration & dosage , Adult , Aged , Autoantibodies/blood , Case-Control Studies , Chronic Disease , Cross-Sectional Studies , Dose-Response Relationship, Drug , Female , Hashimoto Disease/blood , Hashimoto Disease/diagnosis , Hashimoto Disease/epidemiology , Hormone Replacement Therapy/methods , Humans , Hypothyroidism/blood , Hypothyroidism/diagnosis , Hypothyroidism/drug therapy , Hypothyroidism/epidemiology , Longitudinal Studies , Male , Middle Aged , Thyroid Hormones/blood , Thyroiditis/blood , Thyroiditis/diagnosis , Thyroiditis/drug therapy , Thyroiditis/epidemiology , Thyroiditis, Autoimmune/blood , Thyroiditis, Autoimmune/diagnosis , Thyroiditis, Autoimmune/epidemiology , Thyrotropin/blood , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...